GlobeNewswire
-
Medicenna Reports More than Doubling of Median Overall Survival in Glioblastoma Patients With Unresectable Recurrent IDH-WT Tumors Following One Treatment with Bizaxofusp Versus a Matched External Control at SNO 2026
16/11/2026 -
Helus Pharma Announces Positive Topline Results from Phase 3 APPROACH Study evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder
16/11/2026 -
Noom to Bundle a New Wearable, Noom Band, Into Its Popular Enterprise Obesity Care Programs at No Additional Cost
16/11/2026 -
Cardiff Oncology Receives FDA Fast Track Designation for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer
16/11/2026 -
Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results
16/11/2026 -
Apptly Health Technologies Announces Strategic Partnership with BioTrax AI to Bring Precision Longevity Tools to Its Physician Network
16/11/2026 -
Noema Pharma Receives FDA Orphan Drug Designation for Basimglurant for the Treatment of Trigeminal Neuralgia
16/11/2026 -
J-Star Holding Successfully Completes Advanced Composite Skin-to-Structure Welding Trials Built on Proprietary Manufacturing Technology
16/11/2026 -
Instil Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
16/11/2026 -
ToltIQ Chooses ABBYY for Parsing Complex Deal Documents
16/11/2026 -
GT Biopharma Reports Third Quarter 2026 Financial Results
16/11/2026 -
Lumexa Imaging Opens Three New Imaging Centers in November
16/11/2026 -
Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights
16/11/2026 -
Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
16/11/2026 -
Roche’s Gazyva/Gazyvaro becomes the first FDA-approved treatment for primary membranous nephropathy
16/11/2026 -
Lakefront Initiates New €50 Million Share Repurchase Program Following Completion of Initial Share Repurchase Program
16/11/2026 -
FOR INVESTORS AND FINANCIAL AND BUSINESS MEDIA ONLY Renaissance Pharma secures FDA Breakthrough Therapy Designation for daretabart in newly diagnosed high-risk neuroblastoma
16/11/2026 -
Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses
16/11/2026 -
Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer
16/11/2026
Pages